GRAIL, Inc. GRAL

Nasdaq · oncology · unclear · EDGAR · Updated Oct 24, 2026

GRAIL, Inc. (Nasdaq: GRAL) is an oncology diagnostics company.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Program	Indication	Modality	Stage
Galleri	multi-cancer early detection	unclear	NA_NON_THERAPEUTIC

Feb 19, 2026
missed Randomized NHS-Galleri trial (142,000 participants) did not meet its primary endpoint of a statistically significant reduction in Stage III-IV cancers, though Stage IV diagnoses fell by more than 20% in rounds two and three and cancer detection rate rose four-fold.The primary endpoint of statistically significant Stage III-IV reduction was not observed. Filing
Feb 19, 2026
positive Analysis of the full 35,000-participant PATHFINDER 2 study showed performance consistent with the earlier 25,000-participant analysis and a strong safety profile.Completed analysis of the full 35,000 participant PATHFINDER 2 study, demonstrating performance consistent with the 25,000 patient analysis presented in October and a strong safety profile. Filing
Jan 1, 2026
submitted GRAIL completed submission of the final module of the Galleri PMA application to FDA in January 2026.Completed submission of the final module of the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Galleri in January. Filing

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export